NCT07468110 Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke
| NCT ID | NCT07468110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marmara University |
| Condition | Chronic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 47 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2027-02-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 47 participants in total. It began in 2026-03-10 with a primary completion date of 2027-02-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of this study is to evaluate the relationship between the CONUT score, which reflects nutritional status, and balance performance in patients with chronic stroke. The secondary aims are to investigate the association between the CONUT score and functional status and stroke-specific quality of life, as well as to assess the relationships of mid-upper arm circumference, an anthropometric indicator of nutritional status, and ultrasonographic rectus femoris muscle thickness, which reflects muscle mass, with balance performance, functional status, and stroke-specific quality of life. In addition, the study aims to examine the relationships between bone mineral density and balance, functional status, and ambulation level in patients with chronic stroke.
Eligibility Criteria
Inclusion Criteria: * Being 18 years of age or older * Having a diagnosis of ischemic or hemorrhagic stroke * At least 6 months having elapsed since the stroke event (chronic phase) * Being clinically stable * Being able to participate in standing and balance assessments (walking with an assistive device is acceptable) * Having sufficient cognitive capacity to understand and respond to the assessment scales used in the study * Voluntarily agreeing to participate in the study and providing written informed consent Exclusion Criteria: * Acute or subacute stroke phase (\< 6 months) * Inability to administer assessment scales due to severe cognitive impairment or aphasia * Presence of other neurological disorders that may significantly affect balance and functional status (e.g., Parkinson's disease, multiple sclerosis, peripheral neuropathy) * Significant orthopedic conditions unrelated to stroke (e.g., advanced hip or knee osteoarthritis, lower extremity amputation) * Presence of active infection, malignancy, or systemic inflammatory disease (as these conditions may affect the CONUT score) * Cerebellar localization of the cerebrovascular event * History of major surgery or intensive care unit admission within the past 3 months * Inability to safely perform balance tests due to severe visual or hearing impairment * Patients with incomplete laboratory data or insufficient information to calculate the CONUT score
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07468110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Chronic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07468110 currently recruiting?
Yes, NCT07468110 is actively recruiting participants. Contact the research team at fatma.betul820@gmail.com for enrollment information.
Where is the NCT07468110 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07468110 clinical trial?
NCT07468110 is sponsored by Marmara University. The trial plans to enroll 47 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.